Sign in
Taking people in DenmarkPhase 3

Tests divarasib with pembrolizumab against standard chemotherapy in untreated lung cancer

Tests divarasib and pembrolizumab in adults with KRAS G12C-mutated advanced non-squamous lung cancer.

Key facts

Who runs it
F. Hoffmann-La Roche AG
Where
Århus, Copenhagen Oe, Herlev, Herning, Roskilde, and Soenderborg, DenmarkSee the 6 sitesAlso in 11 other countries, 117 sites
Registry title
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Status
Recruiting
Phase
Phase 3
People taking part
282 people, planned
Started
9 Nov 2026
Expected to end
30 Dec 2030
Type of study
Interventional
Record updated
6 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or metastatic non-squamous non-small cell lung cancer who have a KRAS G12C mutation and have had no earlier drug treatment for this cancer.

Age
18 years or older
Sex
All sexes can join
Disease stage
Advanced or metastatic non-squamous non-small cell lung cancer that cannot be treated with surgery or full-dose chemotherapy with radiation meant to remove all of the disease. Measurable disease by RECIST v1.1.
Earlier treatment
No earlier systemic (whole-body) treatment for advanced or metastatic lung cancer.
Biomarker or test result
A KRAS G12C mutation shown by lab testing of a tumor sample, or by an earlier test result on blood or tumor tissue.

Main reasons for not taking part

  • Brain or spinal cord metastases that cause symptoms, are untreated or are actively growing
  • Another known cancer-driving gene change that has an available targeted treatment
  • Earlier treatment with KRAS G12C inhibitors or pan-KRAS/RAS inhibitors
  • Major surgery within 4 weeks before randomization, or a major surgery expected during the study
  • Significant heart or blood vessel disease within 3 months before screening

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, with assessment scale
  • Life expectancy of at least 12 weeks
  • Measurable disease, as defined by RECIST v1.1
  • No prior systemic treatment for advanced or metastatic non−small cell lung cancer (NSCLC)
  • Documentation of the presence of a KRAS G12C mutation either through central laboratory testing of a tumor tissue sample (as per local IVD regulations), or preexisting test results of a blood or tumor tissue sample
  • Histologically or cytologically confirmed diagnosis of advanced or metastatic non-squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy

Who cannot take part

  • Known concomitant second oncogenic driver with available targeted treatment
  • Prior treatment with KRAS G12C inhibitors or pan-KRAS/RAS inhibitors
  • Major surgical procedure within 4 weeks prior to randomization or anticipation of need for a major surgical procedure during the study
  • Palliative radiation to bone metastases within 2 weeks prior to randomization to ensure adequate recovery from the effects of radiotherapy
  • Significant cardiovascular disease within 3 months prior to screening
  • Symptomatic, untreated, or actively progressing CNS metastases

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Which best describes your lung cancer?
  • Has the cancer spread to other parts of the body, or is it too advanced to be removed by surgery?
  • Has your cancer spread to the brain?

Where in Denmark

Also in 11 other countries, 117 sites

  • Aarhus UniversitetshospitalÅrhus, DenmarkTaking people
  • RigshospitaletCopenhagen Oe, DenmarkTaking people
  • Herlev og Gentofte HospitalHerlev, DenmarkTaking people
  • Regionshospitalet GoedstrupHerning, DenmarkTaking people
  • Zealand University HospitalRoskilde, DenmarkTaking people
  • Region SyddanmarkSoenderborg, DenmarkTaking people

About the trial

What the trial wants to find out

To evaluate the efficacy of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin with respect to progression-free survival (PFS) and overall survival (OS)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Plain-language title
Tests divarasib with pembrolizumab against standard chemotherapy in untreated lung cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 10 November 2026.
Fit questions
Built from 2024-518365-10-00, who can take part
Record updated
6 October 2026